Merck, Eisai Decide to Discontinue Advanced Melanoma Therapy Trial

The placebo-controlled, randomised Phase III trial was designed for assessing Merck’s anti-PD-1 therapy Keytruda and Eisai’s Lenvima against Keytruda alone for the first-line treatment of adult patients. The decision to discontinue the clinical trial is based on an independent data monitoring committee recommendation.